426226-20-2

Upstream product

• 84559-56-8 (S)-methyl 2-(4-oxocyclopent-2-en-1-yl)acetate 
• 67920-82-5 (S)-methyl 2-(cyclopent-2-en-1-yl)acetate 
• 20657-21-0 3-acetoxycyclopent-1-ene 
• 3212-60-0 cyclopent-2-enol 
• 930-30-3 cyclopent-2-enone 
• 426226-19-9 (1R,3R)-1-(2-dimethylmalonyl)-3-triphenylmethoxy-4-cyclopentene 
• 426226-17-7 (1R,3R)-1-hydroxy-3-triphenylmethoxy-4-cyclopentene 
• 426225-90-3 (1S,3R)-1-Hydroxy-3-triphenylmethoxy-4-cyclopentene 
• 426226-18-8 (1S,3R)-1-chloro-3-triphenylmethoxy-4-cyclopentene 
• 115074-49-2 (1R,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-cyclopentene-1-yl acetate 
• 120520-91-4 (1R,4S)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enol 
• 60410-16-4 (1R,4S)-4-hydroxy-2-cyclopentene-1-yl acetate 
• 660436-38-4 ((1S,4R)-4-Trityloxy-cyclopent-2-enyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS

In one aspect, the present invention provides novel derivatives of Δ12-PGJ3 and modular synthetic pathways to obtaining Δ12-PGJ3 and derivatives thereof. In some aspects, the present derivatives of Δ12-PGJ3 are useful as chemotherapeutic agents. The present disclosure also describes compositions of these derivatives as well as methods of use of the derivatives thereof.

Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases

The invention concerns pharmaceutical compositions that contain a compound or compounds that can effectively regulate the activity of Type 5 Adenylyl Cyclase and methods for treatment of neurological diseases and disorders, as well as motor function loss

Metal coordination-based inhibitors of adenylyl cyclase: Novel potent P-site antagonists

The adenylyl cyclases (ACs) are a family of intracellular enzymes associated with signal transduction by virtue of their ability to convert ATP to cAMP. The catalytic mechanism of this transformation proceeds through initial binding of ATP to the so-calle